BURLINGAME, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $4.00 per share. All of the 5,000,000 shares are being offered by Pulse Biosciences. In addition, Pulse Biosciences granted the underwriters a 45-day over-allotment option to purchase up to an additional 750,000 shares at the initial public offering price. The shares are expected to begin trading on the NASDAQ Capital Market on May 18, 2016 under the trading symbol "PLSE." The offering is expected to close on May 23, 2016, subject to customary closing conditions.
MDB Capital Group and Feltl and Company are acting as the joint book-running managers for the offering. This offering will be made only by means of a prospectus, copies of which may be obtained from the offices of MDB Capital Group, 2425 Cedar Springs Road, Dallas, Texas 75201 or by email at email@example.com or Feltl and Company, Prospectus Department, 800 LaSalle Avenue, Suite 2100, Minneapolis, MN 55402, telephone: 612-492-8800 or by email at firstname.lastname@example.org.
A registration statement relating to these securities has been filed with, and was declared effective by, the Securities and Exchange Commission on May 13, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pulse Biosciences, Inc.
Pulse Biosciences is a medical device company developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling, or NPES. NPES has been shown in pre-clinical data to provide effective local tumor control and to initiate an adaptive immune response. Pulse Biosciences intends to deploy its NPES platform across a variety of applications, including human oncology, dermatology, aesthetics and other minimally invasive applications where current ablation modalities do not provide comparable benefits.
Contact: Brian Dow Chief Financial Officer email@example.com
Source:Pulse Biosciences, Inc.